Nanomedicines for Renal Disease: Current Status and Future Applications

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2016 Nov 8

PMID 27795549

Citations 76

Authors

Nazila Kamaly

John C He

Dennis A Ausiello

Omid C Farokhzad

Affiliations

Soon will be listed here.

Abstract

Treatment and management of kidney disease currently presents an enormous global burden, and the application of nanotechnology principles to renal disease therapy, although still at an early stage, has profound transformative potential. The increasing translation of nanomedicines to the clinic, alongside research efforts in tissue regeneration and organ-on-a-chip investigations, are likely to provide novel solutions to treat kidney diseases. Our understanding of renal anatomy and of how the biological and physico-chemical properties of nanomedicines (the combination of a nanocarrier and a drug) influence their interactions with renal tissues has improved dramatically. Tailoring of nanomedicines in terms of kidney retention and binding to key membranes and cell populations associated with renal diseases is now possible and greatly enhances their localization, tolerability, and efficacy. This Review outlines nanomedicine characteristics central to improved targeting of renal cells and highlights the prospects, challenges, and opportunities of nanotechnology-mediated therapies for renal diseases.

Citing Articles

Nanomaterials for targeted therapy of kidney diseases: Strategies and advances.

Wang Z, Zhang C Mater Today Bio. 2025; 31:101534.

PMID: 39990736 PMC: 11846943. DOI: 10.1016/j.mtbio.2025.101534.

Nonviral targeted mRNA delivery: principles, progresses, and challenges.

He X, Li G, Huang L, Shi H, Zhong S, Zhao S MedComm (2020). 2025; 6(1):e70035.

PMID: 39760110 PMC: 11695212. DOI: 10.1002/mco2.70035.

Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.

Roointan A, Xu R, Corrie S, Hagemeyer C, Alt K J Am Soc Nephrol. 2024; 36(3):500-518.

PMID: 39705082 PMC: 11888965. DOI: 10.1681/ASN.0000000608.

Targeting cellular senescence in kidney diseases and aging: A focus on mesenchymal stem cells and their paracrine factors.

Hejazian S, Hejazian S, Mostafavi S, Hosseiniyan S, Montazersaheb S, Ardalan M Cell Commun Signal. 2024; 22(1):609.

PMID: 39696575 PMC: 11657437. DOI: 10.1186/s12964-024-01968-1.

PAMAM-Calix-Dendrimers: Third Generation Synthesis and Impact of Generation and Macrocyclic Core Conformation on Hemotoxicity and Calf Thymus DNA Binding.

Mostovaya O, Shiabiev I, Ovchinnikov D, Pysin D, Mukhametzyanov T, Stanavaya A Pharmaceutics. 2024; 16(11).

PMID: 39598503 PMC: 11597237. DOI: 10.3390/pharmaceutics16111379.

References

Money-Kyrle J, Bates F, Ready J, Gazzard B, Phillips R, Boag F . Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol). 1993; 5(6):367-71. DOI: 10.1016/s0936-6555(05)80088-3. View

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

Wilmer M, Ng C, Lanz H, Vulto P, Suter-Dick L, Masereeuw R . Kidney-on-a-Chip Technology for Drug-Induced Nephrotoxicity Screening. Trends Biotechnol. 2015; 34(2):156-170. DOI: 10.1016/j.tibtech.2015.11.001. View

Zheng X, Zhang X, Sun H, Feng B, Li M, Chen G . Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation. 2007; 82(12):1781-6. DOI: 10.1097/01.tp.0000250769.86623.a3. View

Dams E, Laverman P, Oyen W, Storm G, Scherphof G, van der Meer J . Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000; 292(3):1071-9. View

Dolman M, Harmsen S, Storm G, Hennink W, Kok R . Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev. 2010; 62(14):1344-57. DOI: 10.1016/j.addr.2010.07.011. View

Reddy L, Couvreur P . Nanotechnology for therapy and imaging of liver diseases. J Hepatol. 2011; 55(6):1461-6. DOI: 10.1016/j.jhep.2011.05.039. View

Miner J . The glomerular basement membrane. Exp Cell Res. 2012; 318(9):973-8. PMC: 3334451. DOI: 10.1016/j.yexcr.2012.02.031. View

Valencia P, Pridgen E, Perea B, Gadde S, Sweeney C, Kantoff P . Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond). 2012; 8(5):687-98. PMC: 3694785. DOI: 10.2217/nnm.12.134. View

10.

Longmire M, Choyke P, Kobayashi H . Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008; 3(5):703-17. PMC: 3407669. DOI: 10.2217/17435889.3.5.703. View

11.

Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O . First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014; 32(36):4141-8. DOI: 10.1200/JCO.2013.55.0376. View

12.

Pascual D, Borque A . Epidemiology of kidney cancer. Adv Urol. 2008; :782381. PMC: 2581742. DOI: 10.1155/2008/782381. View

13.

Gerlowski L, Jain R . Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986; 31(3):288-305. DOI: 10.1016/0026-2862(86)90018-x. View

14.

Dong Y, Love K, Dorkin J, Sirirungruang S, Zhang Y, Chen D . Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A. 2014; 111(11):3955-60. PMC: 3964096. DOI: 10.1073/pnas.1322937111. View

15.

Li Z, Araoka T, Wu J, Liao H, Li M, Lazo M . 3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. Cell Stem Cell. 2016; 19(4):516-529. PMC: 7832086. DOI: 10.1016/j.stem.2016.07.016. View

16.

Dolman M, Harmsen S, Pieters E, Sparidans R, Lacombe M, Szokol B . Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Int J Nanomedicine. 2012; 7:417-33. PMC: 3273977. DOI: 10.2147/IJN.S26485. View

17.

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

18.

Cedervall T, Lynch I, Foy M, Berggard T, Donnelly S, Cagney G . Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl. 2007; 46(30):5754-6. DOI: 10.1002/anie.200700465. View

19.

Falke L, Gholizadeh S, Goldschmeding R, Kok R, Nguyen T . Diverse origins of the myofibroblast—implications for kidney fibrosis. Nat Rev Nephrol. 2015; 11(4):233-44. DOI: 10.1038/nrneph.2014.246. View

20.

Ibrahim N, Samuels B, Page R, Doval D, Patel K, Rao S . Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23(25):6019-26. DOI: 10.1200/JCO.2005.11.013. View